Erik A. Toso

762 total citations
18 papers, 557 citations indexed

About

Erik A. Toso is a scholar working on Molecular Biology, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Erik A. Toso has authored 18 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Erik A. Toso's work include Muscle Physiology and Disorders (9 papers), RNA Research and Splicing (7 papers) and RNA modifications and cancer (4 papers). Erik A. Toso is often cited by papers focused on Muscle Physiology and Disorders (9 papers), RNA Research and Splicing (7 papers) and RNA modifications and cancer (4 papers). Erik A. Toso collaborates with scholars based in United States, North Macedonia and South Korea. Erik A. Toso's co-authors include Michael Kyba, Darko Bosnakovski, Si Ho Choi, Michael A. Walters, Elizabeth T. Ener, Micah D. Gearhart, Do‐Hyung Kim, Neil Otto, Timothy J. Griffin and Ji‐Man Park and has published in prestigious journals such as Nature Communications, Neurology and Oncogene.

In The Last Decade

Erik A. Toso

18 papers receiving 553 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erik A. Toso United States 12 437 114 90 86 48 18 557
Maysoon Salih Canada 16 402 0.9× 39 0.3× 58 0.6× 116 1.3× 31 0.6× 28 526
Fatima Amor France 9 430 1.0× 23 0.2× 60 0.7× 49 0.6× 75 1.6× 10 474
Hiba Komati Canada 12 334 0.8× 77 0.7× 15 0.2× 123 1.4× 51 1.1× 17 448
W. H. Davin Townley-Tilson United States 8 559 1.3× 59 0.5× 16 0.2× 67 0.8× 32 0.7× 12 727
Evelyne Gicquel France 11 379 0.9× 23 0.2× 63 0.7× 115 1.3× 134 2.8× 17 466
Yuka Nakatani Japan 11 244 0.6× 22 0.2× 121 1.3× 47 0.5× 51 1.1× 26 516
Christin Collins United States 8 210 0.5× 45 0.4× 56 0.6× 34 0.4× 164 3.4× 13 425
Amber Wilson United States 9 267 0.6× 57 0.5× 62 0.7× 13 0.2× 25 0.5× 11 404
Nesrin Sabha Canada 8 223 0.5× 28 0.2× 35 0.4× 38 0.4× 31 0.6× 12 303

Countries citing papers authored by Erik A. Toso

Since Specialization
Citations

This map shows the geographic impact of Erik A. Toso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik A. Toso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik A. Toso more than expected).

Fields of papers citing papers by Erik A. Toso

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik A. Toso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik A. Toso. The network helps show where Erik A. Toso may publish in the future.

Co-authorship network of co-authors of Erik A. Toso

This figure shows the co-authorship network connecting the top 25 collaborators of Erik A. Toso. A scholar is included among the top collaborators of Erik A. Toso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik A. Toso. Erik A. Toso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Bedada, Fikru B., Brian R. Thompson, Sunny Sun-Kin Chan, et al.. (2024). Inducing positive inotropy in human iPSC-derived cardiac muscle by gene editing-based activation of the cardiac α-myosin heavy chain. Scientific Reports. 14(1). 3915–3915. 2 indexed citations
2.
Schneider, Christine A., Jacqueline M. Leung, Erik A. Toso, et al.. (2024). Skin muscle is the initial site of viral replication for arboviral bunyavirus infection. Nature Communications. 15(1). 1121–1121. 6 indexed citations
3.
Bosnakovski, Darko, Erik A. Toso, Elizabeth T. Ener, et al.. (2023). Antagonism among DUX family members evolved from an ancestral toxic single homeodomain protein. iScience. 26(10). 107823–107823. 9 indexed citations
4.
Toso, Erik A., et al.. (2022). Antiapoptotic Protein FAIM2 is targeted by miR-3202, and DUX4 via TRIM21, leading to cell death and defective myogenesis. Cell Death and Disease. 13(4). 405–405. 6 indexed citations
5.
Bosnakovski, Darko, Elizabeth T. Ener, Mark S. Cooper, et al.. (2021). Inactivation of the CIC-DUX4 oncogene through P300/CBP inhibition, a therapeutic approach for CIC-DUX4 sarcoma. Oncogenesis. 10(10). 68–68. 21 indexed citations
6.
Melon, Christophe, Pascal Salin, Erik A. Toso, et al.. (2021). Enhanced differentiation of human induced pluripotent stem cells toward the midbrain dopaminergic neuron lineage through GLYPICAN-4 downregulation. Stem Cells Translational Medicine. 10(5). 725–742. 8 indexed citations
7.
Bosnakovski, Darko, Meiricris Tomaz da Silva, Elizabeth T. Ener, et al.. (2019). A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death. Science Advances. 5(9). eaaw7781–eaaw7781. 52 indexed citations
8.
Lee, John K., Darko Bosnakovski, Erik A. Toso, et al.. (2018). Crystal Structure of the Double Homeodomain of DUX4 in Complex with DNA. Cell Reports. 25(11). 2955–2962.e3. 24 indexed citations
9.
Bosnakovski, Darko, Micah D. Gearhart, Erik A. Toso, et al.. (2018). Low level DUX4 expression disrupts myogenesis through deregulation of myogenic gene expression. Scientific Reports. 8(1). 16957–16957. 37 indexed citations
10.
Park, Ji‐Man, Minchul Seo, Chang Hwa Jung, et al.. (2018). ULK1 phosphorylates Ser30 of BECN1 in association with ATG14 to stimulate autophagy induction. Autophagy. 14(4). 584–597. 135 indexed citations
11.
Bosnakovski, Darko, Micah D. Gearhart, Erik A. Toso, et al.. (2017). p53-independent DUX4 pathology. Disease Models & Mechanisms. 10(10). 1211–1216. 23 indexed citations
12.
Bosnakovski, Darko, Erik A. Toso, Lynn M. Hartweck, et al.. (2017). The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain. Journal of Cell Science. 130(21). 3685–3697. 48 indexed citations
13.
Choi, Si Ho, Darko Bosnakovski, Jessica M. Strasser, et al.. (2016). Transcriptional Inhibitors Identified in a 160,000-Compound Small-Molecule DUX4 Viability Screen. SLAS DISCOVERY. 21(7). 680–688. 13 indexed citations
14.
Zhang, Yu, John K. Lee, Erik A. Toso, et al.. (2015). DNA-binding sequence specificity of DUX4. Skeletal Muscle. 6(1). 8–8. 31 indexed citations
15.
Filareto, Antonio, Fabrizio Rinaldi, Robert W. Arpke, et al.. (2015). Pax3-induced expansion enables the genetic correction of dystrophic satellite cells. Skeletal Muscle. 5(1). 36–36. 11 indexed citations
16.
Bosnakovski, Darko, Si Ho Choi, Jessica M. Strasser, et al.. (2014). High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity. Skeletal Muscle. 4(1). 4–4. 55 indexed citations
17.
Hartweck, Lynn M., Lindsey Anderson, Richard J.L.F. Lemmers, et al.. (2013). A focal domain of extreme demethylation within D4Z4 in FSHD2. Neurology. 80(4). 392–399. 57 indexed citations
18.
Maggi, Leonard B., et al.. (2009). Nucleophosmin protein expression level, but not threonine 198 phosphorylation, is essential in growth and proliferation. Oncogene. 28(36). 3209–3220. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026